LT2534132T - Pakeistieji pirolidin-2-karboksamidai - Google Patents
Pakeistieji pirolidin-2-karboksamidaiInfo
- Publication number
- LT2534132T LT2534132T LTEP11702449.7T LT11702449T LT2534132T LT 2534132 T LT2534132 T LT 2534132T LT 11702449 T LT11702449 T LT 11702449T LT 2534132 T LT2534132 T LT 2534132T
- Authority
- LT
- Lithuania
- Prior art keywords
- carboxamides
- substituted pyrrolidine
- pyrrolidine
- substituted
- Prior art date
Links
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical class NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/702,402 US8354444B2 (en) | 2008-09-18 | 2010-02-09 | Substituted pyrrolidine-2-carboxamides |
| PCT/EP2011/051619 WO2011098398A1 (en) | 2010-02-09 | 2011-02-04 | Substituted pyrrolidine-2-carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2534132T true LT2534132T (lt) | 2017-07-10 |
Family
ID=43608850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11702449.7T LT2534132T (lt) | 2010-02-09 | 2011-02-04 | Pakeistieji pirolidin-2-karboksamidai |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8354444B2 (lt) |
| EP (1) | EP2534132B1 (lt) |
| JP (1) | JP5612710B2 (lt) |
| KR (1) | KR101461298B1 (lt) |
| CN (1) | CN102753522B (lt) |
| AR (2) | AR080143A1 (lt) |
| AU (1) | AU2011214506C1 (lt) |
| BR (1) | BR112012019672B1 (lt) |
| CA (1) | CA2788236C (lt) |
| CL (1) | CL2012002189A1 (lt) |
| CR (1) | CR20120410A (lt) |
| CY (1) | CY1119049T1 (lt) |
| DK (1) | DK2534132T3 (lt) |
| EC (1) | ECSP12012083A (lt) |
| ES (1) | ES2629439T3 (lt) |
| HK (1) | HK1171452A1 (lt) |
| HR (1) | HRP20170903T1 (lt) |
| HU (1) | HUE034816T2 (lt) |
| LT (1) | LT2534132T (lt) |
| MX (1) | MX2012009186A (lt) |
| MY (1) | MY165238A (lt) |
| NZ (1) | NZ601422A (lt) |
| PE (1) | PE20121532A1 (lt) |
| PL (1) | PL2534132T3 (lt) |
| PT (1) | PT2534132T (lt) |
| RS (1) | RS56163B1 (lt) |
| RU (1) | RU2564022C2 (lt) |
| SG (1) | SG182763A1 (lt) |
| SI (1) | SI2534132T1 (lt) |
| TW (1) | TWI401243B (lt) |
| UA (1) | UA107954C2 (lt) |
| WO (1) | WO2011098398A1 (lt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7303676B2 (en) * | 2003-02-13 | 2007-12-04 | Zenon Technology Partnership | Supported biofilm apparatus and process |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| MX2012004377A (es) | 2009-10-14 | 2012-06-01 | Merck Sharp & Dohme | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos. |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| SI2684880T1 (en) | 2011-03-10 | 2018-08-31 | Daiichi Sankyo Company, Limited | DERIVAT DISPIROPYROLIDINE |
| WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20140200255A1 (en) * | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
| CN107540594A (zh) * | 2012-05-30 | 2018-01-05 | 霍夫曼-拉罗奇有限公司 | 取代的吡咯烷‑2‑甲酰胺 |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| AR094116A1 (es) | 2012-12-20 | 2015-07-08 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de hdm2 |
| WO2014114575A1 (en) * | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| PL2958893T3 (pl) * | 2013-02-21 | 2017-09-29 | F.Hoffmann-La Roche Ag | Asymetryczna synteza podstawionego pirolidyno-2-karboksyamidu |
| US20140275562A1 (en) * | 2013-03-13 | 2014-09-18 | Dow Agrosciences Llc | Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto |
| KR20160009677A (ko) * | 2013-06-19 | 2016-01-26 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합 |
| JP6239745B2 (ja) * | 2013-06-19 | 2017-11-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの処置のための、ｒｏ５５０３７８１及びカペシタビンの組み合わせ |
| WO2014206866A1 (en) * | 2013-06-24 | 2014-12-31 | F. Hoffmann-La Roche Ag | Stable intravenous formulation |
| RU2016101514A (ru) * | 2013-07-03 | 2017-08-08 | Ф. Хоффманн-Ля Рош Аг | ЭКСПРЕССИЯ мРНК ГЕНОВ ДЛЯ ПЕРСОНАЛИЗАЦИИ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ ПАЦИЕНТОВ АНТАГОНИСТОМ MDM2 |
| SI3077004T1 (sl) | 2013-12-05 | 2020-07-31 | F. Hoffmann-La Roche Ag | Novo kombinirano zdravilo za akutno mieloično levkemijo (AML) |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| MA39877A (fr) * | 2014-04-15 | 2017-02-22 | Hoffmann La Roche | Formes solides d'un composé pharmaceutiquement actif |
| SG11201608667SA (en) | 2014-04-17 | 2016-11-29 | Univ Michigan | Mdm2 inhibitors and therapeutic methods using the same |
| JP6162646B2 (ja) * | 2014-05-27 | 2017-07-12 | 信越化学工業株式会社 | ３，５−ジメチルドデカン酸の製造方法 |
| EP3204776B1 (en) * | 2014-10-10 | 2019-09-04 | F.Hoffmann-La Roche Ag | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
| EP3277677B9 (en) * | 2015-03-30 | 2021-07-14 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| KR102122469B1 (ko) | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
| CA3048088C (en) | 2016-12-30 | 2021-05-04 | Oriental (Luzhou) Agrochemicals. Co., Ltd. | Method for preparing 2-(cyclohexenylidene) malonic acid derivatives and uses thereof |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| MA49566A (fr) | 2017-07-11 | 2020-05-20 | Vertex Pharma | Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques |
| CN108586195A (zh) * | 2017-12-27 | 2018-09-28 | 北京汇康博源医药科技有限公司 | 一种5-羟基-7，7-二甲基-2h-茚酮的制备方法 |
| WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
| AR120680A1 (es) | 2019-12-06 | 2022-03-09 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
| AR126073A1 (es) | 2021-06-04 | 2023-09-06 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN116459225B (zh) * | 2023-04-26 | 2023-11-10 | 东莞市金美济药业有限公司 | 一种艾拉戈克钠片及其制备工艺 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732902A (en) | 1986-05-23 | 1988-03-22 | Hoffmann-La Roche Inc. | Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| US6353023B1 (en) | 1997-08-28 | 2002-03-05 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| CN1294120C (zh) * | 2003-10-21 | 2007-01-10 | 山东大学 | 吡咯烷类基质金属蛋白酶抑制剂及其应用 |
| US7550487B2 (en) * | 2004-03-26 | 2009-06-23 | Hoffmann-La Roche Inc. | Pyrrolidine-3,4-dicarboxamide derivatives |
| JP5248866B2 (ja) * | 2005-02-22 | 2013-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ｍｄｍ２の小分子阻害剤およびその使用 |
| NZ561215A (en) * | 2005-02-22 | 2010-12-24 | Univ Michigan | Small molecule inhibitors of MDM2 and uses thereof |
| EP1893601A1 (en) | 2005-06-17 | 2008-03-05 | AstraZeneca AB | Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives |
| KR20090042779A (ko) * | 2006-06-30 | 2009-04-30 | 쉐링 코포레이션 | Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용 |
| WO2008067909A2 (de) | 2006-12-06 | 2008-06-12 | Sanofi-Aventis | Harnstoff- und sulfamidderivate als inhibitoren von tafia |
| WO2009004383A2 (en) | 2007-07-03 | 2009-01-08 | Astrazeneca Ab | Aza-bicyclohexane compounds useful as anticoagulants |
| JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
| US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| NZ589671A (en) | 2008-06-06 | 2012-03-30 | Sanofi Aventis | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
| CA2727925A1 (en) | 2008-06-23 | 2009-12-30 | Astrazeneca Ab | New heterocyclic carboxamides for use as thrombin inhibitors |
| GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| PE20110367A1 (es) | 2008-09-18 | 2011-06-13 | Hoffmann La Roche | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 |
| US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
-
2010
- 2010-02-09 US US12/702,402 patent/US8354444B2/en active Active
-
2011
- 2011-02-04 NZ NZ601422A patent/NZ601422A/en unknown
- 2011-02-04 BR BR112012019672-3A patent/BR112012019672B1/pt active IP Right Grant
- 2011-02-04 EP EP11702449.7A patent/EP2534132B1/en active Active
- 2011-02-04 CN CN2011800089274A patent/CN102753522B/zh active Active
- 2011-02-04 PL PL11702449T patent/PL2534132T3/pl unknown
- 2011-02-04 PE PE2012001184A patent/PE20121532A1/es active IP Right Grant
- 2011-02-04 WO PCT/EP2011/051619 patent/WO2011098398A1/en active Application Filing
- 2011-02-04 ES ES11702449.7T patent/ES2629439T3/es active Active
- 2011-02-04 LT LTEP11702449.7T patent/LT2534132T/lt unknown
- 2011-02-04 DK DK11702449.7T patent/DK2534132T3/en active
- 2011-02-04 SI SI201131222T patent/SI2534132T1/sl unknown
- 2011-02-04 MY MYPI2012003543A patent/MY165238A/en unknown
- 2011-02-04 CA CA2788236A patent/CA2788236C/en active Active
- 2011-02-04 HU HUE11702449A patent/HUE034816T2/en unknown
- 2011-02-04 PT PT117024497T patent/PT2534132T/pt unknown
- 2011-02-04 SG SG2012055752A patent/SG182763A1/en unknown
- 2011-02-04 RU RU2012138257/04A patent/RU2564022C2/ru active
- 2011-02-04 JP JP2012552343A patent/JP5612710B2/ja active Active
- 2011-02-04 AU AU2011214506A patent/AU2011214506C1/en active Active
- 2011-02-04 KR KR1020127023297A patent/KR101461298B1/ko active IP Right Grant
- 2011-02-04 MX MX2012009186A patent/MX2012009186A/es active IP Right Grant
- 2011-02-04 RS RS20170658A patent/RS56163B1/sr unknown
- 2011-02-07 AR ARP110100393A patent/AR080143A1/es active IP Right Grant
- 2011-02-08 TW TW100104166A patent/TWI401243B/zh active
- 2011-04-02 UA UAA201210421A patent/UA107954C2/ru unknown
-
2012
- 2012-08-03 EC ECSP12012083 patent/ECSP12012083A/es unknown
- 2012-08-07 CL CL2012002189A patent/CL2012002189A1/es unknown
- 2012-08-07 CR CR20120410A patent/CR20120410A/es unknown
- 2012-11-29 HK HK12112287.3A patent/HK1171452A1/xx unknown
-
2017
- 2017-06-13 HR HRP20170903TT patent/HRP20170903T1/hr unknown
- 2017-06-23 CY CY20171100673T patent/CY1119049T1/el unknown
-
2018
- 2018-12-13 AR ARP180103640A patent/AR114159A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3607A (en) | Substituted imidazopyridazines | |
| DK3342786T3 (en) | Anti-dll3-antistof | |
| AP3107A (en) | 5-Alkynyl-pyrimidines | |
| HK1171452A1 (en) | Substituted pyrrolidine-2-carboxamides -2- | |
| EP2566479A4 (en) | AZA-INDAZOLES | |
| EP2640189A4 (en) | 3-deutero-pomalidomide | |
| EP2651505A4 (en) | ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION | |
| DK3466977T3 (en) | Anti-vla-4-antistoffer | |
| EP2641891A4 (en) | PKC ACTIVATOR- | |
| HK1188782A1 (en) | Substituted sodium-1h-pyrazole-5-olate 1h--5- | |
| GB201010016D0 (en) | Armacat | |
| AU4536P (en) | TB01 Tibouchina urvilleana | |
| AU4937P (en) | FlatinsulGL Myoporum insulare | |
| AU4822P (en) | FlatwaxwhiteGL Chamelaucium uncinatum | |
| AU4931P (en) | FlatwaxDarkGL Chamelaucium uncinatum | |
| AU4932P (en) | FlatwaxpinkGL Chamelaucium uncinatum | |
| AU2010194V (en) | CalpenGL Calothamnus quadrifidus | |
| AU2010165V (en) | Silversunrise Conostylis candicans | |
| GB201001209D0 (en) | Magnastud | |
| GB201000799D0 (en) | 2velcrose | |
| GB201000765D0 (en) | Koolkilt | |
| GB201000706D0 (en) | Kilthanger | |
| GB201000547D0 (en) | Jurasic | |
| GB201000203D0 (en) | Formits | |
| GB201000246D0 (en) | Head-kase |